Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
2019 · New England Journal of Medicine · 2,479 citations
https://doi.org/10.1056/nejmoa1816047
B
Brian I. Rini
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.3K
Papers
77.4K
Citations
122
h-index
568
i10-index
Brian I. Rini is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Renal cell carcinoma treatment & Renal and related cancers & Cancer Genomics and Diagnostics. The author has an h-index of 122, co-authored 1127 publications.
ORCID: 0000-0002-2212-080XPapers by this author
worksAtezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
2019 · The Lancet · 988 citations
https://doi.org/10.1016/s0140-6736(19)30723-8
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
2010 · Journal of Clinical Oncology · 788 citations
https://doi.org/10.1200/jco.2009.26.5561
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
2020 · Cancer Cell · 532 citations
https://doi.org/10.1016/j.ccell.2020.10.011
HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism
2017 · Nature Communications · 462 citations
https://doi.org/10.1038/s41467-017-01965-8
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
2020 · Annals of Oncology · 454 citations
https://doi.org/10.1016/j.annonc.2020.04.010
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat